ASX:PME.AX 18 February 2026 - 4 March 2026

Pro Medicus shares rose 1.7% to A$116.19 Wednesday, rebounding after an 8.77% drop the previous session. The S&P/ASX 200 fell 1.9% amid Middle East tensions and rate-hike concerns. Co-founders bought A$3.4 million in shares, with no new company news reported. Traders await the Reserve Bank’s March 17 decision and Pro Medicus’ March 20 dividend.

Pro Medicus shares fell 2.35% to A$123.00 Wednesday, extending a 43% drop for 2026 despite the S&P/ASX 200 closing higher. Directors Anthony Glenning and Deena Shiff bought shares on Feb. 13. The company reported half-year revenue of A$124.8 million and statutory profit after tax of A$171.2 million, boosted by a fair-value gain. Pro Medicus declared a 32-cent interim dividend, ex-dividend Feb. 26, payable March 20.